Menu
This WP will analyse a specific set of 50 ageing/HF-associated circulating ncRNAs. This set will be derived from WP1 & WP2, comprehensive literature searches, mining of databases (e.g. gene expression omnibus) and from unpublished findings of consortium members.
Available to EXPERT are various healthy and diseased human cohorts complete with plasma/serum samples for ncRNA measurements and existing data on ageing characteristics, diverse relevant CVD-related clinical events and relevant co-morbidities and confounders.
The overall aim of WP3 is to generate and test a small, well-defined panel of age-related ncRNAs in available large clinical and population-based cohorts (n >10,000 individuals and >50,000 patient years of follow up, see table below).
Cohorts Name | n of subjects w/ available samples | Mean Age (y) | Male (%) | Cardiac disease | Follow-up (FU) | Type of samples available |
|---|---|---|---|---|---|---|
STANISLAS | >4000 @V1 ≥1600 @V4 | 27±14 49±14 | 50 48 | Natural age-associated CVD | Every 5-y after enrolment Total of 18-y FU (@V4) | V4: 250μl serum 250μl plasma. V1-V3 smaller volumes |
EPHESUS | 451 @ V1 | 62±11 | 76 | Post-MI | Up to 15 months | 250μl serum or 250μl plasma |
REMI | 111 | 56±9 | 89 | Post-MI | 6 months | 250μl serum or 250μl plasma |
AURORA | 2,776 | 64±8 | 60 | End stage renal disease | >48 months | 250μl serum or 250μl plasma |
ALCHEMIST | 800 | on-going | on-going | End stage renal disease | >48 months | 250μl serum or 250μl plasma |
Hannover HCM | >110 (recruiting) | on-going | on-going | Hypertrophic cardiomyopathy | 3 years | 250μl serum or 250μl plasma |
PESA | 4066 | 45.8±4.3 | 63 | No (CVD-Free) | Every 3-y after enrolment. Total of 6-y FU (@V3) | 250μl serum |
